Jennifer Marvin‐Peek

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

Courtney D. DiNardo, Jennifer Marvin‐Peek, Sanam Loghavi et al. · Journal of Clinical Oncology · 2025 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia

Wei‐Ying Jen, Jennifer Marvin‐Peek, Hagop M. Kantarjian et al. · Cancer · 2024 · 17 citations · Full text

Medicine, Hematology, Pharmacology +12

FcγRIIb on CD11c+ cells modulates serum cholesterol and triglyceride levels and differentially affects atherosclerosis in male and female Ldlr mice

Jennifer Marvin‐Peek, Jillian P. Rhoads, Amy S. Major · Atherosclerosis · 2019 · 16 citations · Full text

Life Sciences, Immunology, Pathology +16

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Jennifer Marvin‐Peek, Jacqueline S. Garcia, Gautam Borthakur et al. · Blood · 2024 · 16 citations

Medicine, Hematology, Pharmacotherapy +12

Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

Jayastu Senapati, Sanam Loghavi, Jennifer Marvin‐Peek et al. · American Journal of Hematology · 2025 · 11 citations · Full text

Medicine, Hematology, Oncology +15